



(51) International Patent Classification:

C12N 5/0781 (2010.01) C12N 5/0786 (2010.01)
C12N 5/0784 (2010.01)

(21) International Application Number:

PCT/US2022/012935

(22) International Filing Date:

19 January 2022 (19.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/139,680 20 January 2021 (20.01.2021) US

(71) Applicant: **NEOGENE THERAPEUTICS B.V.**
[NL/NL]; Science Park 106, 1098 XG Amsterdam (NL).

(72) Inventors: **SCHUMACHER, Antonius, Nicolaas, Maria**; Science Park 106, 1098 XG Amsterdam (NL). **LIN-NEMANN, Carsten**; Science Park 106, 1098 XG Amsterdam (NL). **KUILMAN, Thomas**; Science Park 106, 1098 XG Amsterdam (NL). **BENDLE, Gavin, M.**; Science Park 106, 1098 XG Amsterdam (NL). **GADIOT, Jules, F.C.**; Science Park 106, 1098 XG Amsterdam (NL). **VAN HEIJST, Jeroen, W.J.**; Science Park 106, 1098 XG Amsterdam (NL). **GOMEZ-EERLAND, Raquel**; Science Park 106, 1098 XG Amsterdam (NL). **SCHRIKKEMA, Deborah, Sophie**; Science Park 106, 1098 XG Amsterdam (NL). **WALKER, Julia, Zoe**; Science Park 106, 1098 XG Am-

sterdam (NL). **BIES, Laura**; Science Park 106, 1098 XG Amsterdam (NL).

(74) Agent: **ACHTSAM, Jessica, L.**; 2040 Main Street, 14th Floor, Irvine, California 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ENGINEERED ANTIGEN PRESENTING CELLS

Figure 2. An engineered cell may include one or more of the following features.

- a) has been adjusted to induce, enhance and/or maintain its survival in vitro;
- b) has been incubated with at least one antigen compound; and
- c) has at least one genetic modification to induce, enhance, maintain or modify antigen-presentation by the cell.

FIG. 2

(57) Abstract: Provided herein are various engineered antigen presenting cells, methods of making them and methods of using them.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*